Clinical-economic appropriateness of drug treatments: Designing a method that combines evidence-based information and cost assessments to construct league tables accounting for the potential number of patients

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 11, 2004, Pages 2381-2389

  Messori, Andrea ^a   Santarlasci, Benedetta ^a   Trippoli, Sabrina ^a   Vaiani, Monica ^a   Vacca, Franca ^a   Brutti, M Chiara ^b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b MINISTRY OF HEALTH   (Italy)

Author keywords

Clinical economic appropriateness; Costs; Effectiveness

Indexed keywords

ALENDRONIC ACID; AROMATASE INHIBITOR; BETA INTERFERON; CELECOXIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; LAMIVUDINE; MEGESTROL; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

BREAST CANCER; BUDGET; COST EFFECTIVENESS ANALYSIS; DEPRESSION; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; HEALTH CARE QUALITY; HEALTH STATUS; HEPATITIS B; HUMAN; ISCHEMIC HEART DISEASE; MULTIPLE SCLEROSIS; OSTEOARTHRITIS; PATIENT CARE; PHARMACEUTICAL CARE; PHARMACOEPIDEMIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; THEORETICAL STUDY;

ACTUARIAL ANALYSIS; COST-BENEFIT ANALYSIS; DRUG THERAPY; ECONOMICS, PHARMACEUTICAL; EVIDENCE-BASED MEDICINE; HUMANS; ITALY; MORBIDITY;

EID: 8544252453     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.11.2381     Document Type: Review

References (18)

1. JOHANNESSON M, JONSSON B, KJEKSHUS J, OLSSON AG, PEDERSEN TR, WEDEL H: Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N. Engl. J. Med. (1997) 336(5 ):332-336.
2. SPIEGEL BM, TARGOWNIK L, DULAI GS, GRALNEK IM: The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann. Intern. Med. (2003) 138 10):795-806.
3. MAETZEL A, KRAHN M, NAGLIE G: The cost-effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum. (2003) 49(3):283-92.
4. MAUSKOPF J, RUTTEN F, SCHONFELD W. Cost-effectiveness league tables: valuable guidance for decision makers? Pharmacoeconomics (2003) 21(14):991-1000.
5. ROSS SD, ALLEN IE, CONNELLY JE et al.: Clinical outcomes in statin treatment trials: a meta-analysis. Arch. Intern. Med. (1999) 159(15):1793-1802.
6. KOBELT G, JONSSON L, MILTENBURGER C, JONSSON B: Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data. Int. J. Technol. Assess. Health Care (2002) 18(1):127-138.
7. REVICKI DA, BROWN RE, KELLER MB, GONZALES J, CULPEPPER L, HALES RE: Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J. Clin. Psychiatry (1997) 58(2):47-58.
8. WONG JB, SINGH G, KAVANAUGH A: Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am. J. Med. (2002) 113(5):400-408.
9. JOHNELL O, JONSSON B, JONSSON L, BLACK D: Cost effectiveness of alendronate (Fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics (2003) 21(5):305-314.
10. SPIEGEL BM, TARGOWNIK L, DULAI GS, GRALNEK IM: The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann. Intern. Med. (2003) 138 10):795-806.
11. MAETZEL A, KRAHN M, NAGLIE G: The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum. (2003) 49(3):283-292.
12. MESSORI A, CATTEL F, TRIPPOLI S, VAIANI M: Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol. Anticancer Drugs (2000) 11(9):701-706.
13. DRANITSARIS G, VERMA S, TRUDEAU M: Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen. Am. J. Clin. Oncol. (2003) 26 3):289-296.
14. ORLEWSKA E: The cost-effectiveness of alternative therapeutic strategies for the management of chronic hepatitis B in Poland. Value Health (2002) 5(5):404-420.
15. CROWLEY SJ, TOGNARINI D, DESMOND PV, LEES M: Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics (2000) 17(5):409-427.
16. ROSENHECK R, CRAMER J, XU W et al.: A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N. Engl. J. Med. (1997) 337(12):809-815.
17. MARSHALL T: Coronary heart disease prevention: insights from modelling incremental cost effectiveness. Br. Med. J. (2003) 327 1264.
18. WARBURTON RN: What do we gain from the sixth coronary heart disease drug? Br. Med. J. (2003) 327:1237-1238.